Lars Lindholm Sorensen1, Hsin-Yueh Liang2, Aurelio Pinheiro3, Alex Hilser3, Veronica Dimaano3, Niels Thue Olsen4, Thomas Fritz Hansen5, Peter Sogaard6, Alexandra Nowbar3, Chiara Pisanello3, Iraklis Pozios3, Susan Phillip3, Xun Zhou3, Roselle Abraham3, Theodore P Abraham7. 1. Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD; Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark. 2. Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD; China Medical University, Taichung, Taiwan. 3. Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD. 4. Department of Cardiology, Rigshospitalet, Copenhagen, Denmark. 5. Department of Cardiology, Gentofte Hospital, Copenhagen, Denmark. 6. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. 7. Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: tabraha3@jhmi.edu.
Abstract
BACKGROUND: Exercise echocardiography in the evaluation of hypertrophic cardiomyopathy (HCM) provides valuable information for risk stratification, selection of optimal treatment, and prognostication. However, HCM patients with left ventricular outflow tract gradients ≥30mm Hg are often excluded from exercise testing because of safety considerations. We examined the safety and utility of exercise testing in patients with high-gradient HCM. METHODS: We evaluated clinical characteristics, hemodynamics, and imaging variables in 499 consecutive patients with HCM who performed 959 exercise tests. Patients were divided based on peak left ventricular outflow tract gradients using a 30-mm Hg threshold into the following: obstructive (n=152), labile-obstructive (n=178), and nonobstructive (n=169) groups. RESULTS: There were no deaths during exercise testing. We noted 20 complications (2.1% of tests) including 3 serious ventricular arrhythmias (0.3% of tests). There was no difference in complication rate between groups. Patients with obstructive HCM had a higher frequency of abnormal blood pressure response (obstructive: 53% vs labile: obstructive: 41% and nonobstructive: 37%; P=.008). Obstructive patients also displayed a lower work capacity (obstructive: 8.4±3.4 vs labile obstructive: 10.9±4.2 and nonobstructive: 10.2±4.0, metabolic equivalent; P<.001). Exercise testing provided incremental information regarding sudden cardiac death risk in 19% of patients with high-gradient HCM, and we found a poor correlation between patient-reported functional class and work capacity. CONCLUSION: Our results suggest that exercise testing in HCM is safe, and serious adverse events are rare. Although numbers are limited, exercise testing in high-gradient HCM appears to confer no significant additional safety hazard in our selected cohort and could potentially provide valuable information.
BACKGROUND: Exercise echocardiography in the evaluation of hypertrophic cardiomyopathy (HCM) provides valuable information for risk stratification, selection of optimal treatment, and prognostication. However, HCM patients with left ventricular outflow tract gradients ≥30mm Hg are often excluded from exercise testing because of safety considerations. We examined the safety and utility of exercise testing in patients with high-gradient HCM. METHODS: We evaluated clinical characteristics, hemodynamics, and imaging variables in 499 consecutive patients with HCM who performed 959 exercise tests. Patients were divided based on peak left ventricular outflow tract gradients using a 30-mm Hg threshold into the following: obstructive (n=152), labile-obstructive (n=178), and nonobstructive (n=169) groups. RESULTS: There were no deaths during exercise testing. We noted 20 complications (2.1% of tests) including 3 serious ventricular arrhythmias (0.3% of tests). There was no difference in complication rate between groups. Patients with obstructive HCM had a higher frequency of abnormal blood pressure response (obstructive: 53% vs labile: obstructive: 41% and nonobstructive: 37%; P=.008). Obstructive patients also displayed a lower work capacity (obstructive: 8.4±3.4 vs labile obstructive: 10.9±4.2 and nonobstructive: 10.2±4.0, metabolic equivalent; P<.001). Exercise testing provided incremental information regarding sudden cardiac death risk in 19% of patients with high-gradient HCM, and we found a poor correlation between patient-reported functional class and work capacity. CONCLUSION: Our results suggest that exercise testing in HCM is safe, and serious adverse events are rare. Although numbers are limited, exercise testing in high-gradient HCM appears to confer no significant additional safety hazard in our selected cohort and could potentially provide valuable information.
Authors: Raymond J Gibbons; Gary J Balady; J Timothy Bricker; Bernard R Chaitman; Gerald F Fletcher; Victor F Froelicher; Daniel B Mark; Ben D McCallister; Aryan N Mooss; Michael G O'Reilly; William L Winters; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Richard O Russell; Sidney C Smith Journal: Circulation Date: 2002-10-01 Impact factor: 29.690
Authors: Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy Journal: Circulation Date: 2011-11-08 Impact factor: 29.690
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Domenico Corrado; Antonio Pelliccia; Hein Heidbuchel; Sanjay Sharma; Mark Link; Cristina Basso; Alessandro Biffi; Gianfranco Buja; Pietro Delise; Ihor Gussac; Aris Anastasakis; Mats Borjesson; Hans Halvor Bjørnstad; François Carrè; Asterios Deligiannis; Dorian Dugmore; Robert Fagard; Jan Hoogsteen; Klaus P Mellwig; Nicole Panhuyzen-Goedkoop; Erik Solberg; Luc Vanhees; Jonathan Drezner; N A Mark Estes; Sabino Iliceto; Barry J Maron; Roberto Peidro; Peter J Schwartz; Ricardo Stein; Gaetano Thiene; Paolo Zeppilli; William J McKenna Journal: Eur Heart J Date: 2009-11-20 Impact factor: 29.983
Authors: Martin S Maron; Iacopo Olivotto; Sandro Betocchi; Susan A Casey; John R Lesser; Maria A Losi; Franco Cecchi; Barry J Maron Journal: N Engl J Med Date: 2003-01-23 Impact factor: 91.245
Authors: Barry J Maron; Paolo Spirito; Win-Kuang Shen; Tammy S Haas; Francesco Formisano; Mark S Link; Andrew E Epstein; Adrian K Almquist; James P Daubert; Thorsten Lawrenz; Giuseppe Boriani; N A Mark Estes; Stefano Favale; Marco Piccininno; Stephen L Winters; Massimo Santini; Sandro Betocchi; Fernando Arribas; Mark V Sherrid; Gianfranco Buja; Christopher Semsarian; Paolo Bruzzi Journal: JAMA Date: 2007-07-25 Impact factor: 56.272
Authors: Sholeh Bazrafshan; Robert Sibilia; Saavia Girgla; Shiv Kumar Viswanathan; Megan J Puckelwartz; Kiranpal S Sangha; Rohit R Singh; Mashhood Kakroo; Roman Jandarov; David M Harris; Jack Rubinstein; Richard C Becker; Elizabeth M McNally; Sakthivel Sadayappan Journal: Front Cardiovasc Med Date: 2021-12-23
Authors: Kellsey N Smith; Tracy Baynard; Peter S Fischbach; Jane S Hankins; Lewis L Hsu; Peggy M Murphy; Kiri K Ness; Shlomit Radom-Aizik; Amy Tang; Robert I Liem Journal: Br J Sports Med Date: 2021-07-20 Impact factor: 18.473